financetom
Business
financetom
/
Business
/
Serina Therapeutics Names Simba Gill as Executive Chairman
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Serina Therapeutics Names Simba Gill as Executive Chairman
Apr 17, 2024 3:14 PM

05:52 PM EDT, 04/17/2024 (MT Newswires) -- Serina Therapeutics ( SER ) said late Wednesday it appointed Simba Gill as executive chairman.

The company said Gill has served in "key roles" at various firms, including Maxygen and Systemix.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Bolt Biotherapeutics Q3 collaboration revenue doubles
Bolt Biotherapeutics Q3 collaboration revenue doubles
Nov 12, 2025
Overview * Bolt Biotherapeutics ( BOLT ) Q3 collaboration revenue rises to $2.2 mln, doubling from last year * Company's net loss for Q3 narrows significantly compared to the same period last year * Cash balance of $38.8 mln expected to fund operations into 2027 Outlook * Company anticipates cash balance to fund operations into 2027 * Bolt seeks partner...
Southland Q3 revenue up 23.1% 
Southland Q3 revenue up 23.1% 
Nov 12, 2025
Overview * Southland Q3 revenue rises 23.1% yr/yr but misses analyst expectations * Company reports Q3 gross profit margin of 1.5%, improving from a loss last year * Net loss impacted by non-cash tax charge and legacy project adjustments Outlook * Company did not provide specific future guidance in the statement Result Drivers * CIVIL SEGMENT - Strength in civil...
WEBTOON Entertainment Q3 Adjusted Earnings Fall, Revenue Rises; Shares Fall After Hours
WEBTOON Entertainment Q3 Adjusted Earnings Fall, Revenue Rises; Shares Fall After Hours
Nov 12, 2025
04:38 PM EST, 11/12/2025 (MT Newswires) -- Webtoon Entertainment ( WBTN ) reported Q3 adjusted earnings late Wednesday of $0.04 per diluted share, down from $0.22 a year earlier. Two analysts polled by FactSet expected a loss of $0.10. Revenue in the three months ended Sept. 30 rose to $378.0 million from $347.9 million a year earlier. Analysts surveyed by...
Plby Group Q3 revenue misses estimates
Plby Group Q3 revenue misses estimates
Nov 12, 2025
Overview * Plby Group Q3 revenue of $29 mln missed analyst expectations * Adjusted EBITDA for Q3 beats estimates, reflecting improved operational efficiency * Company extends senior debt maturity to 2028, strengthening financial position Outlook * Company focuses on growth in licensing, media, and hospitality * Plby Group plans to expand global reach with high-margin revenue initiatives Result Drivers *...
Copyright 2023-2026 - www.financetom.com All Rights Reserved